The effect of tolterodine compared with oxybutynin on daytime sleepiness in patients with obstructive sleep apnea

The effect of tolterodine compared with oxybutynin on daytime sleepiness in patients with obstructive sleep apnea: an open-label randomized clinical trial study (open label)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160926029976N7

Enrollment

Registered

2025-11-04

Start date

2025-11-22

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea. Obstructive sleep apnea (adult) (pediatric)

Interventions

Intervention 1: Intervention group: The first intervention group will receive drug treatment with tolterodine (Hakim Company) 4 mg daily for one month. Intervention 2: Intervention group: The second i

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 80 years Have moderate to severe risk for obstructive sleep apnea based on a standard questionnaire

Exclusion criteria

Exclusion criteria: Pregnancy Medication allergy Previous history of glaucoma Benign prostatic hyperplasia Urinary retention Facial abnormalities Neurological and cognitive disorders, schizophrenia, bipolar disorder, and use of drugs affecting the central nervous system History of constipation History of narcolepsy Inability to sleep on your back

Design outcomes

Primary

Measure	Time frame
Daytime sleepiness. Timepoint: Before treatment and one month after starting treatment. Method of measurement: STOP-BANG Standard Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Mohseni Ahangar

Babol University of Medical Sciences

r.mohseni@mubabol.ac.ir+98 11 3223 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026